secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2026-04-07T23:59:59+00:00
Accession:  0001493152-26-015413
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma enters agreement with Univ. of Minnesota for Phase 1a/1b trial of GTB-5550
--------------------------------------------------------------------------------

- Agreement for IND 169118 GTB-5550 (camB7-H3 TriKE) in advanced solid tumors that failed prior therapy.
- University of Minnesota will sponsor as investigator-initiated Phase 1a/1b trial.
- Budget of up to $3.8 million over three years, funded by GT Biopharma.
- Agreement effective April 3, 2026; 30-day termination clause for either party.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000149315226015413/0001493152-26-015413-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000149315226015413/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-015413

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer